All Updates

All Updates

icon
Filter
Partnerships
Roche and PathAI partner to develop AI-enabled digital pathology algorithms for CDx tools
AI Drug Discovery
Feb 12, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 12, 2024

Roche and PathAI partner to develop AI-enabled digital pathology algorithms for CDx tools

Partnerships

  • Drug discovery and development company Roche and bioinformatics company PathAI have partnered to allow PathAI to work exclusively with Roche Tissue Diagnostics to create AI-driven digital pathology algorithms for CDx tools. The image analysis algorithms resulting from this partnership will be deployed through Roche's Navify digital pathology solution.

  • The exclusivity of the partnership would last a specified period, during which PathAI will be the only external company developing AI-based algorithms for Roche Tissue Diagnostics in the CDx tools field. According to the partnership terms, Roche would continue its own algorithm development for CDx tools, while PathAI can pursue algorithm development outside of this realm.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.